eISSN: 2345-4202  
J Nephropharmacol. 2018;7(2):50-54.

Review

Beyond renoprotective impact; ameliorative effects of metformin on malignancies

Nozar Dorestan 1, Mohammad Bahadoram 2, Mohammadreza Khosravi 3, Sara Bahadoram 4, Mohammad Davoodi 5, Maedeh Barahman 6 *

1 Department of Surgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Medical Student Research Committee and Social Determinant of Health Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Pediatrics, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Radiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
6 Department of Radiation Oncology, Firoozgar Hospital, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran
*Corresponding author: Maedeh Barahman, Email: Email: maedeh.barahman@gmail.com

Abstract

Diabetes therapies were associated with either a reduced or increased risk of cancer. There are continuous discussions about a possible protective action of metformin. In fact, metformin, a commonly consumed anti-diabetic medication has an ameliorative impact on some cancers by direct (preventing cell growth and apoptosis) and indirect (increasing insulin sensitivity) effects. Observational reports have suggested which metformin reduces the incidence of few common cancers. In general, metformin is an extensively recommended anti-diabetic medication with a recognized ability coupled with a satisfactory and safety profile and inexpensive. This review article considers reduction and protective abilities of metformin on cancers especially prostate, liver, breast, lung, and colon cancer.

Implication for health policy/practice/research/medical education:

Metformin, a commonly consumed anti-diabetic medication, has an ameliorative impact on some cancers by direct (preventing cell growth and apoptosis) and indirect (increasing insulin sensitivity) effects.

Please cite this paper as: Dorestan N, Bahadoram M, Khosravi M, Bahadoram S, Davoodi M, Barahman M. Beyond renoprotective impact; ameliorative effects of metformin on malignancies. J Nephropharmacol. 2017;7(2):50-54.

First name
 
Last name
 
Email address
 
Comments
 
Security code


Submitted: 14 Nov 2017

Accepted: 20 Feb 2018
First published online: 03 Mar 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

Abstract Page Views: 242
PDF Downloads: 397
Full Text Views: 0